Krystal Biotech to Unveil KB409/410 PCD Data and KB407, KB707 Trial Updates
Krystal Biotech will present HSV-1 gene therapy data for KB409/KB410 on May 12, 2026, targeting primary ciliary dyskinesia at the ASGCT Annual Meeting. It will also report interim CORAL-1 results for KB407 in cystic fibrosis on May 20 and phase 1/2 KB707 plus pembrolizumab data in NSCLC on May 31.
1. ASGCT Annual Meeting Presentation
On May 12, 2026, Krystal Biotech will present a poster on KB409 and KB410, two HSV-1–based gene therapy vectors targeting primary ciliary dyskinesia, led by Bruce Nmezi, PhD, from 5:00PM to 6:30PM ET.
2. ATS International Conference Oral Presentation
On May 20, 2026 at 10:03AM ET, Jorge Lascano, MD, will deliver interim CORAL-1 trial results of KB407 for cystic fibrosis as an oral presentation at the ATS conference.
3. ASCO Annual Meeting Immunotherapy Poster
On May 31, 2026 from 9:00AM to 12:00PM CT, Wen Wee Ma, MBBS, will present phase 1/2 data on inhaled KB707 combined with pembrolizumab for advanced non-small cell lung cancer.
4. Company Pipeline and Commercial Stage
Krystal Biotech is a commercial-stage genetic medicine company whose first approved product, VYJUVEK® gene therapy, treats dystrophic epidermolysis bullosa; the firm is advancing a robust pipeline including KB409, KB410, KB407 and KB707.